Literature DB >> 16513453

Accumulation of celecoxib with a 7-fold higher drug exposure in individuals homozygous for CYP2C9*3.

Mia Sandberg Lundblad, Staffan Ohlsson, Peter Johansson, Pierre Lafolie, Erik Eliasson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16513453     DOI： 10.1016/j.clpt.2005.11.007

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  7 in total

1.  Pharmacokinetic drug interactions of the selective androgen receptor modulator GTx-024(Enobosarm) with itraconazole, rifampin, probenecid, celecoxib and rosuvastatin.

Authors:  Christopher C Coss; Amanda Jones; James T Dalton
Journal:  Invest New Drugs       Date:  2016-04-22       Impact factor: 3.850

2.  Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Authors:  Andrew T Chan; Ann G Zauber; Meier Hsu; Aurora Breazna; David J Hunter; Rebecca B Rosenstein; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

Review 3.  Clinical use and pharmacological properties of selective COX-2 inhibitors.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2007-11-13       Impact factor: 2.953

4.  Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles.

Authors:  Lioubov I Brueggemann; Alexander R Mackie; Bharath K Mani; Leanne L Cribbs; Kenneth L Byron
Journal:  Mol Pharmacol       Date:  2009-07-15       Impact factor: 4.436

5.  Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.

Authors:  Scott D Solomon; Janet Wittes; Peter V Finn; Robert Fowler; Jaye Viner; Monica M Bertagnolli; Nadir Arber; Bernard Levin; Curtis L Meinert; Barbara Martin; Joseph L Pater; Paul E Goss; Peter Lance; Stefanie Obara; Emily Y Chew; Jonghyeon Kim; Gretchen Arndt; Ernest Hawk
Journal:  Circulation       Date:  2008-03-31       Impact factor: 29.690

Review 6.  The pharmacogenomics of pain management: prospects for personalized medicine.

Authors:  Sonya Ting; Stephan Schug
Journal:  J Pain Res       Date:  2016-02-10       Impact factor: 3.133

7.  Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.

Authors:  Young-Hoon Kim; Pureum Kang; Chang-Keun Cho; Eui Hyun Jung; Hye-Jeong Park; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-07-25       Impact factor: 4.946
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.